It’s a Deal: Revance Therapeutics Accepts Crown’s Increased Offer
Revance Therapeutics has accepted an amended bid from Crown Laboratories that ups the purchase price to $3.65 a share from $3.10. Under the terms of the revised merger agreement, which has been unanimously approved by the Revance Board of Directors, Revance’s stockholders will receive $3.65 per share of common stock, par value $0.001 per share in cash, without interest […]